EGFR and non-small cell lung carcinoma: A prior meta-analysis of 27 selected studies which included nearly 4000 patients with NSCLC revealed a pooled sensitivity of 60% and specificity of 94% for the detection of EGFR mutations in the plasma or serum [45].